NCT05924620

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: a Randomized, Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Chongqing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To study the efficacy and safety of finerenone in patients with primary aldosteronism

Detailed description

This is a prospective and randomized study involving patients with primary aldosteronism(PA). All paticipants will be randomized into finerenone group(Intervention group) and spironolactone group(Control group) and to compare the antihypertensive effect in patients with PA. If the self-measured blood pressure of patients at home continues to be greater than 140/90 mmHg at 2-4 weeks, spironolactone or finerenone should be increased to 40mg qd, and electrolytes should be reviewed at 2 weeks after dosed.

Conditions

• Primary Aldosteronism

Interventions

Type	Name	Description
DRUG	finerenone	Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).

Timeline

• Start date: 2023-06-21
• Primary completion: 2024-03-12
• Completion: 2024-03-12
• First posted: 2023-06-29
• Last updated: 2024-06-18

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study